Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Palatin Technologies, Inc. Common Stock (NY:PTN)

16.60 -0.41 (-2.41%)
Streaming Delayed Price Updated: 10:02 AM EST, Jan 9, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Press Releases about Palatin Technologies, Inc. Common Stock

Palatin’s Oral Obesity Drug Shows Remarkable Results: The Hidden Gem in the Weight Loss Race
Via AB Newswire
News headline image
Palatin Technologies’ UC Treatment Shows Remarkable 78% Clinical Response Rate in Phase 2 Topline Data – Potential Game-Changer for Millions Suffering from Ulcerative Colitis (NYSE: PTN)
Via AB Newswire
News headline image
Palatin Technologies’ Obesity Drug Receives FDA Orphan Designation; Phase 2 Results Imminent (NYSE: PTN)
Via AB Newswire
News headline image
Cosette Pharmaceuticals Acquires Vyleesi® (Bremelanotide Injection) from Palatin Technologies Inc.
From Cosette Pharmaceuticals, Inc.
Via Business Wire
Melanocortin Receptor R&D to Target Increasing Prevalence of Obesity-Related Disorders
EQNX::TICKER_START (NYSE:PTN),(NASDAQ:RYTM),(NASDAQ:VKTX),(NASDAQ:GPCR),(NYSE:NVO) EQNX::TICKER_END 
Via FinancialNewsMedia
Biotech Market Update: Global Pharmaceuticals Market Expected to Reach $1.5 Trillion by Year’s End
EQNX::TICKER_START (NYSE:PTN),(NASDAQ:CRDF),(NASDAQ:BDRX),(NASDAQ:DRUG),(NYSE:LLY) EQNX::TICKER_END 
Via FinancialNewsMedia
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.